Sign In
Buy VCNX
$0.85
+0.0181 (+2.19%)
At Close: Jul 31, 2026
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
08:30am, Wednesday, 27'th Mar 2024
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
08:00am, Wednesday, 21'st Feb 2024
Eight new antibody discovery agreements incorporate Vaccinex's powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against ch
Vaccinex, Inc. Announces Reverse Stock Split
08:00am, Thursday, 15'th Feb 2024
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
08:00am, Wednesday, 07'th Feb 2024
ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to t
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
08:00am, Monday, 04'th Dec 2023
Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer's Disease on Schedule to Complete Treatment in June 2024 ROCHESTER,
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
08:00am, Monday, 13'th Nov 2023
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer's Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new financing du
Pepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with h
Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch
11:00am, Thursday, 26'th Oct 2023
If you're wondering what is going on in the stock market today or which penny stocks to buy now that major indexes are lower, you're not alone. Earnings season mixed with economic data has resulted in
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
09:30am, Thursday, 26'th Oct 2023
Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient blood Pepinemab, anti-SEMA4D bl
Why Is Vaccinex (VCNX) Stock Up 26% Today?
08:08am, Friday, 06'th Oct 2023
Vaccinex (NASDAQ: VCNX ) stock is climbing higher on Friday after the clinical-stage biotechnology company announced insider buying. These insider trading actions were revealed by Vaccinex in a serie
Vaccinex Announces Pricing of $9.6 Million Public Offering
09:00pm, Thursday, 28'th Sep 2023
ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to
Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their “native conformation” so as to efficiently induce and select
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
08:00am, Wednesday, 27'th Sep 2023
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be reviewed on September 28 at CHI's 20th Annual Discovery on Target (DOT)
"Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease” will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimer's Disease
Vaccinex, Inc. Announces Reverse Stock Split
04:30pm, Friday, 22'nd Sep 2023
ROCHESTER, N.Y., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease an
